<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00428974</url>
  </required_header>
  <id_info>
    <org_study_id>CF101-201PS</org_study_id>
    <nct_id>NCT00428974</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of CF101 to Treat Psoriasis</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Can-Fite BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Can-Fite BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that CF101, which is under development to treat other
      immune-mediated inflammatory diseases, will provide clinical benefits in the treatment of
      chronic plaque psoriasis. Patients with psoriasis who qualify for the study will be treated
      every 12 hours (q12h) with CF101 capsules, or placebo capsules, for 12 weeks. The safety of
      treatment will be carefully assessed through clinical and laboratory monitoring. The effect
      of treatment on psoriasis will be evaluated through standard techniques of examination and
      measurement of the severity of skin involvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multicenter, randomized, double-blind, dose-ranging, placebo-controlled,
      study in adult males and females, ages 18 to 70 years, inclusive, with a diagnosis of
      moderate-to-severe chronic plaque psoriasis. At the Screening Visit, patients who provide
      written informed consent will have screening procedures performed, including a complete
      medical history, medication history, physical examination, including height, weight, blood
      pressure, pulse rate and temperature, and clinical laboratory tests.

      Eligible patients will be those who have not received systemic retinoids, corticosteroids, or
      immunosuppressants (e.g., methotrexate, cyclosporine) within 6 weeks prior to initiation of
      study; or high potency topical corticosteroids (Class I-III), keratolytics, or coal tar
      (other than on the scalp, palms, groin, and/or soles); and UV or Dead Sea therapy within 4
      weeks prior to initiation of study treatment. Eligible patients will be sequentially assigned
      to 1 of 3 dosing cohorts:

      Cohort 1: CF101 1 mg (15 patients) or Placebo (5 patients); Cohort 2: CF101 2 mg (15
      patients) or Placebo (5 patients); Cohort 3: CF101 4 mg (15 patients) or Placebo (5
      patients).

      Medication will be taken orally q12h for 12 weeks. Disease activity will be assessed using
      the Psoriasis Area and Severity Index (PASI) and the Physician Global Assessment (PGA).
      Patients will return for assessments at Weeks 2, 4, 8, 12 and 14.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score</measure>
    <time_frame>12 weeks minus baseline</time_frame>
    <description>PASI scale is sum of redness, thickness, and scale scores, ranging from 0 (no disease) to 72 (most severe possible score); lower scores, i..e., negative change from baseline, indicate improvement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and Nature of Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Who Achieve a Score of &quot;Almost Clear&quot; or &quot;Clear&quot; by Physician's Global Assessment (PGA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>PGA is a scale from 0 (clear, no disease) to 5 (most severe score); patients who improve to 0 (clear) or 1 (minimal disease) are tabulated in this outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual PASI Components Redness, Thickness, and Scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>Each component is scored as 0 (clear, no disease) to 24 (most severe score); lower scores indicate improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Peripheral Blood Mononuclear Cell Adenosine A3 Receptor (A3AR) Expression Level at Baseline and Response to Therapy.</measure>
    <time_frame>12 weeks</time_frame>
    <description>A3AR is measured biochemically and the expression level on cells from patients with disease is compared to that from healthy volunteer levels and expressed as a ratio</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF101</intervention_name>
    <description>CF101 1 mg q12 hours for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>IB-MECA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF101</intervention_name>
    <description>CF101 2 mg q12 hours for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>IB-MECA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF101</intervention_name>
    <description>CF101 4 mg q12 hours for 12 weeks</description>
    <arm_group_label>3</arm_group_label>
    <other_name>IB-MECA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets q12 hours for 12 weeks</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Inactive pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 to 70 years of age, inclusive;

          -  Diagnosis of moderate-to-severe chronic plaque-type psoriasis with body surface area
             involvement ≥10%, as judged by the Investigator;

          -  Duration of psoriasis of at least 6 months;

          -  PASI score ≥10;

          -  Body weight ≤100 kg;

          -  Candidate for systemic treatment or phototherapy for psoriasis;

          -  ECG is normal or shows abnormalities which, in the judgment of the Investigator, are
             not clinically significant;

          -  Females of child-bearing potential must have a negative serum pregnancy test at
             screening;

          -  Females of child-bearing potential must be willing to use 2 methods of contraception
             deemed adequate by the Investigator (for example oral contraceptive pills plus a
             barrier method) to be eligible for, and continue participation in, the study;

          -  Ability to complete the study in compliance with the protocol; and

          -  Ability to understand and provide written informed consent.

        Exclusion Criteria:

          -  Erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis;

          -  Treatment with systemic retinoids, corticosteroids, or immunosuppressants (e.g.,
             methotrexate, cyclosporine) within 6 weeks of the Baseline visit;

          -  Treatment with high potency topical corticosteroids (Class I-III), keratolytics, or
             coal tar (other than on the scalp, palms, groin, and/or soles) within 2 weeks of the
             Baseline visit;

          -  Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit, or anticipated
             need for either of these therapies during the study period;

          -  Treatment with a biological agent (including etanercept, adalimumab, efalizumab,
             infliximab, or alefacept) within a period of time equal to 5 times its circulating
             half-life, or 30 days, whichever is longer, prior to the Baseline visit;

          -  History of poor clinical response to methotrexate after an adequate regimen and
             duration of treatment;

          -  Treatment with systemic nonsteroidal anti-inflammatory drugs, beta-blockers, lithium,
             hydroxychloroquine, chloroquine, or systemic terbinafine within 2 weeks of the
             Baseline visit, or anticipated need for such drugs during the study period;

          -  Presence or history of uncontrolled asthma;

          -  Presence or history of uncontrolled arterial hypertension or symptomatic hypotension;

          -  Significant cardiac arrhythmia or conduction block, congestive heart failure (New York
             Heart Association Class 3-4), or any other evidence of clinically significant heart
             disease or clinically significant findings on screening electrocardiogram;

          -  Hemoglobin level &lt;9.0 gm/L;

          -  Platelet count &lt;125,000/mm^3;

          -  White blood cell count &lt;3500/mm^3;

          -  Serum creatinine level greater than 1.5 times the laboratory's upper limit of normal;

          -  Liver aminotransferase levels greater than 2 times the laboratory's upper limit of
             normal;

          -  Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the
             Investigator;

          -  History of malignancy within the past 5 years (excluding basal cell carcinoma of the
             skin and ≤3 cutaneous squamous cell carcinomas, all of which have been completely
             excised);

          -  Significant acute or chronic medical or psychiatric illness that, in the judgment of
             the Investigator, could compromise patient safety, limit the patient's ability to
             complete the study, and/or compromise the objectives of the study;

          -  Participation in another investigational drug or vaccine trial concurrently or within
             30 days; or within 5 half lives of a biological investigational product, whichever is
             longer;

          -  Other conditions which would confound the study evaluations or endanger the safety of
             the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael David, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haemek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, Yankova R, Kouzeva V, Ramon M, Silverman MH, Fishman P. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol. 2012 Mar;26(3):361-7. doi: 10.1111/j.1468-3083.2011.04078.x. Epub 2011 Apr 20.</citation>
    <PMID>21504485</PMID>
  </results_reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2007</study_first_submitted>
  <study_first_submitted_qc>January 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2007</study_first_posted>
  <results_first_submitted>June 20, 2011</results_first_submitted>
  <results_first_submitted_qc>August 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2011</results_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CF101 1 mg Twice Daily (BID)</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>CF101 2 mg BID</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>CF101 4 mg BID</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25">one patient was randomized but never received study treatment</participants>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CF101 1 mg Twice Daily (BID)</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>CF101 2 mg BID</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>CF101 4 mg BID</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="19"/>
            <count group_id="B5" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" spread="12.0"/>
                    <measurement group_id="B2" value="48.4" spread="10.2"/>
                    <measurement group_id="B3" value="45.3" spread="12.1"/>
                    <measurement group_id="B4" value="51.2" spread="10.4"/>
                    <measurement group_id="B5" value="49.5" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score</title>
        <description>PASI scale is sum of redness, thickness, and scale scores, ranging from 0 (no disease) to 72 (most severe possible score); lower scores, i..e., negative change from baseline, indicate improvement</description>
        <time_frame>12 weeks minus baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CF101 1 mg Twice Daily (BID)</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>CF101 2 mg BID</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>CF101 4 mg BID</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score</title>
          <description>PASI scale is sum of redness, thickness, and scale scores, ranging from 0 (no disease) to 72 (most severe possible score); lower scores, i..e., negative change from baseline, indicate improvement</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="8.9"/>
                    <measurement group_id="O2" value="-8.8" spread="7.0"/>
                    <measurement group_id="O3" value="-4.1" spread="7.8"/>
                    <measurement group_id="O4" value="-2.7" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency and Nature of Adverse Events</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Who Achieve a Score of &quot;Almost Clear&quot; or &quot;Clear&quot; by Physician's Global Assessment (PGA)</title>
        <description>PGA is a scale from 0 (clear, no disease) to 5 (most severe score); patients who improve to 0 (clear) or 1 (minimal disease) are tabulated in this outcome</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CF101 1 mg BID</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>CF101 2 mg BID</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>CF101 4 mg BID</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Who Achieve a Score of &quot;Almost Clear&quot; or &quot;Clear&quot; by Physician's Global Assessment (PGA)</title>
          <description>PGA is a scale from 0 (clear, no disease) to 5 (most severe score); patients who improve to 0 (clear) or 1 (minimal disease) are tabulated in this outcome</description>
          <units>Number of treated patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual PASI Components Redness, Thickness, and Scale</title>
        <description>Each component is scored as 0 (clear, no disease) to 24 (most severe score); lower scores indicate improvement</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Peripheral Blood Mononuclear Cell Adenosine A3 Receptor (A3AR) Expression Level at Baseline and Response to Therapy.</title>
        <description>A3AR is measured biochemically and the expression level on cells from patients with disease is compared to that from healthy volunteer levels and expressed as a ratio</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 weeks</time_frame>
      <desc>All adverse events were collected and verbatim terms were coded via MedDRA dictionary</desc>
      <group_list>
        <group group_id="E1">
          <title>CF101 1 mg Twice Daily (BID)</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>CF101 2 mg BID</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>CF101 4 mg BID</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Oral tablets given every 12 hours for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine oxalate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pnina Fishman, PhD</name_or_title>
      <organization>Can-Fite BioPharma Ltd</organization>
      <phone>011972 3 924 1114</phone>
      <email>pnina@canfite.co.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

